MARKERS IN BREAST CANCER

Abstract
Breast cancer is one of the most common tumors in women and major cause of death and mortality. In view of the heterogeneity of this neoplasia in terms of its biological profile and clinical course, the need of reliable parameters is important to predict accurately prognosis and to indicate a suitable therapy for each patient.Classical prognostic markers in primary breast carcinoma are tumor size, nodal status, histopathology, nuclear degree, distant metastasis and patient age. The presence of steroid receptors serves predominantly as an indicator of hormone responsiveness. Ploidy and proliferative capacity are the most well characterized prognostic factors. All these markers have been shown to predict disease-free survival and whole survival in lymph node negative and positive patients. Additional prognostic and predictive markers such as oncogenes , growth factors, enzymes and recently transcriptional factors appear to characterize the behavior of the breast tumor respect to differentiation degree, growth rate, disease-free survival and metastasis risk.

Bibliografía del artículo

1. Chrzan P. Skolowski J, Karmolinski A et al. Amplification of c-myc gene and overexpression of c.Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin. Biochem. (2001) 34:557-562
2. Debies MT, Welch DR. Genetic basis of human breast cancer metastasis. J.Mammary. Gland.Biol.Neoplasia (2001) 6:441-451
3. Wascher RA, Huynh KT, Giuliano AE et al. Stanniocalcin-1. A novel molecular blood and bone marrow marker for human breast cancer. Clin.Can.Res.(2003) 9: 1427-1435
4. Rochefort H, Garcia M, Glondu M et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin.Chim.Acta 291 (2000): 157-170
5. Billgren AM, Rutqvist LE, Johansson H et al. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen. Eur.J.Cancer 36 (2000): 1374-1380
6. Scorilas A, Talieri M, Ardavanis A et al. Polyadenylate polymerase activity in mammary tumor cytosols: a new independent prognostic marker in primary breast cancer. Can. Res. 60(19):5427
7. Yousef GM, Scorilas A, Magklara A et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast. Br.J.Cancer (2002), 87:1294-1300
8. Yousef GM, Polymeris ME, Grass L et al. Human Kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Can.Res. (2003) 63(14): 3958- 65
9. Maass N, Nagasaki K, Ziebart M et al. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin. Breast Cancer (2002) 3(4): 281-287
10. Mohsin SK, Zhang M, Clark GM et al. Maspin expression in invasive breast cancer: association with other prognostic factors. J.Pathol.(2003) 199:432-435
11. Duffy MJ. Urokinase plasminogen activador and itsinhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin.Chem. (2002) 48: 1194-1197
12. Sidoni A, Cavalieri GA, D\'Amico G et al. Biopathological significance of single cell DNA aneuploidy measured by static cytometry in breast cancer. The Breast (2001) 10:, 325-329
13. Takei H, Iino Y, Horiguchi J et al. Higest microvessel count as a long-term prognostic factor in Japanase breast cancer patients. Cancer .Lett (2000)156: 109-116
14. Gasparini G Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit. Rev.Oncol. Hematol.(2001) 37: 97-114
15. Boyle J. Histological mesurement of tumour angiogenesis. Eur. J. Cancer (2003) 39: 859-860
16. Gion M, Mione R, Leon AE, Luftner D et al. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur.J.Cancer (2001) 37: 355-363
17. Berois N, Varangot M, Sonora C Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5b mRNA. Int J.Cancer (2003) 103(4): 550-555
18. Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J.Clin.Oncol. (2002) 20(16): 3404-3412
19. Xenidis N, Vlachonikolis I, Mavroudis D et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemoterapy in patients with operable breast cancer. Ann.Oncol. (2003) 14(6): 849-855.
20. Spizzo G, Gastl G, Wolf D et al. Correlation of Cox-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br.J.Cancer (2003) 88: 574-578
21. Spizzo G, Obrist P, Ensinger C et al. Prognostic significance of EP-CAM and Her-2/neu overexpression in invasive breast cancer. Int.J.Cancer (2002) 98(6):883-888
22. Cayre A, Rossignol F, Clottes E et al. A HIF but not HIF-1 transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res.(2003), 5: 223-230

Autoevaluación